

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Regenerative Medicine International Limited

中國再生醫學國際有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8158)

PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION

The board (the “**Board**”) of directors (the “**Directors**”) of China Regenerative Medicine International Limited (the “**Company**”) has proposed to amend certain provisions of its second amended and restated memorandum of association and third amended and restated articles of association (the “**Existing M&A**”) for the purpose of, among others, to (i) allow the Company’s general meeting to be held in the form of hybrid meeting and provide for voting by electronic means at general meetings of the Company; (ii) facilitate the implementation of the uncertificated securities market regime; (iii) allow the Company to adopt the implied consent mechanism for disseminating corporate communications by electronic means; and (iv) incorporate other housekeeping amendments (the “**Proposed Amendments**”).

The adoption of the Proposed Amendments are subject to the approval of the shareholders of the Company (the “**Shareholders**”) by way of a special resolution at the upcoming annual general meeting of the Company (the “**AGM**”).

A circular containing, among other matters, details of the Proposed Amendments to the Existing M&A, together with a notice of the AGM, will be published and/or despatched to the Shareholders in due course.

By Order of the Board

China Regenerative Medicine International Limited

Wang Chuang

Chairman, Chief Executive Officer and Executive Director

Hong Kong, 30 April 2026

As at the date of this announcement, the executive Director is Mr. Wang Chuang (Chairman and Chief Executive Officer); the non-executive Director is Ms. Luo Min; and the independent non-executive Directors are Ms. Huo Chunyu, Mr. Zhou Xudong and Mr. Leung Man Fai.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of the Stock Exchange at www.hkexnews.hk for at least seven days from the date of its publication. This announcement will also be published on the Company’s website at www.crmi.hk.